Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05641896 · ClinicalTrials.gov registry record · Phase 2
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
A Phase 2 study, sponsored by SOFIE.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT05641896 is a Phase 2 study that has completed, run by SOFIE. The registered enrollment target is 109 participants.
The verdict
NCT05641896, a Phase 2 study, has completed, sponsored by SOFIE.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of \[18F\]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and colorectal cancer. The \[18F\]FAPI-74 PET scan will be acquired in patients with proven GI cancers after initial staging using institutional standard methods. The PET scan results will be compared to FAP immunohistochemistry (as the primary objective) and histopathology (as the secondary objective) of the biopsied or resected tissues.
Interventions
- DRUG [18F]FAPI-74 PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2023-04-28 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05641896
The ClinicalTrials.gov registry entry for NCT05641896 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SOFIE, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]FAPI-74 PET/CT is the first listed.
NCT05641896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05641896 about?
NCT05641896 is a clinical study titled "Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers". Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of \[18F\]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and colorectal cancer. The \[18F\]...
What is the current status of trial NCT05641896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2023-04-28. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT05641896?
The interventions under investigation include: [18F]FAPI-74 PET/CT (DRUG).
Who is sponsoring clinical trial NCT05641896?
This trial is sponsored by SOFIE, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.